I. Project Name: Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project II. Project Overview: The Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project, invested and developed by Beijing Minhai Biotechnology Co., Ltd., is located on parcels 0503‑039, 040, 043, and 044 within the Daxing Biomedical Industry Base. The project’s boundaries are as follows: north to Simiao Road; south to the planned land boundary (municipal green space); west to Xiangrui Avenue; and east to Tianfu Avenue. This project is primarily intended for the research, development, and production of human vaccines. Construction Scale: The total land area is 90,013.218 m², with a total floor area of 187,684.83 m² (including 130,410.84 m² above ground and 57,273.99 m² underground). Building heights range from 33.3 meters, with one basement level and seven above‑ground floors. Basement floor-to-floor heights are 6 meters, while above‑ground heights vary between 3.8 and 7.9 meters. The green space ratio is 15%, the floor area ratio is 1.5, and the building density is 40%. Design Period: October 2020 – October 2021. III. Scope of Tender: 1. Scope of Tender: This tender covers interior fit‑out design and exterior curtain wall design for the Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project. a) Interior Fit‑Out Design: Key tasks include: - Conceptual design (including animation walkthroughs, renderings, and preparation of design documentation); - Schematic design (including animation walkthroughs, renderings, and preparation of design documentation); - Construction drawing design; - General contracting for interior fit‑out works (coordinating with laboratory and cleanroom engineering specialists). b) Exterior Curtain Wall Design: Key tasks include: - Detailed schematic design (including animation walkthroughs, renderings, and preparation of design documentation); - Construction drawing design. 2. Design Scope (specific floor areas are listed in the table below): - Interior fit‑out design for public areas in Buildings No. 1, 8, 9, and 10; - Interior fit‑out design for Buildings No. 2, 3, 13, 14, and 15; - Interior fit‑out design for the civil‑use portion of Building No. 12; - Exterior curtain wall design for Buildings No. 1 through 15. 3. Floor Areas: | No. | Project Type | Total Floor Area (m²) | Above‑Ground Floor Area (m²) | Below‑Ground Floor Area (m²) | Number of Floors | Height (m) | |-----|--------------|-----------------------|-------------------------------|-------------------------------|-----------------|------------| | 1 | R&D Pilot Plant | 41,596.95 | 41,596.95 | — | 6 | 13.18–6.0 | | 2 | R&D Technical Workshop | 14,852.14 | 14,852.14 | — | 7 | 13.16–6.0 | | 3 | Comprehensive Service Building | 14,040.32 | 14,040.32 | — | 6 | 12.45–6.0 | | 8 | Vaccine Production Building | 16,771.16 | 16,771.16 | — | 4 | 13.3–6.0 | | 9 | Packaging and Warehousing Building | 15,765.58 | 15,765.58 | — | 4 | 13.3–6.0 | | 10 | Bacterial Vaccine Production Building | 19,807.00 | 19,807.00 | — | 4 | 13.3–6.0 | | 11 | Basement Level 12 | 55,933.02 | 55,933.02 | 55,933.94 | 13.9–6.0 | | 12 | Gatehouse and Carport Level 13 | 370.80 | 370.80 | — | 13.9–6.0 | | 13 | Gatehouse Level 14 | 29.83 | 29.83 | — | 13.9–6.0 | | 14 | Gatehouse Level 15 | 59.66 | 59.66 | — | 13.9–6.0 | IV. Registration Instructions: 1. Participating entities must submit the following documents: business license, qualification certificates, legal representative certificate or power of attorney, and a copy of the legal representative’s ID card (copies must bear the official seal of the company), along with details of the company’s registered capital. 2. Bidders must possess qualifications in both interior fit‑out design and exterior curtain wall design. Additionally, the applying organization and its lead design team must have demonstrated experience in the following areas: - Interior fit‑out projects for national or provincial public venues, such as expo centers, convention centers, art centers, and cultural halls; - Interior fit‑out projects for office spaces of national, provincial, or Fortune Global 500 companies, including headquarters, office buildings, and conference centers; - Interior fit‑out projects for residential, hotel, and apartment developments among China’s top ten real estate developers; - Exterior curtain wall projects for national or provincial public venues, office spaces, or pharmaceutical industrial parks. 3. Registrants must provide contact information for a designated representative, who should be the project manager or an appointed liaison, along with proof of social insurance coverage for the past 12 months. 4. The tenderer will review all submitted qualification documents, giving priority to applicants with relevant project experience, and will conduct further discussions and site visits with shortlisted candidates. 5. Beijing Minhai Biotechnology Co., Ltd. was established in 2004 and is a wholly owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. (a publicly listed company). For more information, please visit the company’s website. V. Registration Details: 1. After registering by phone, bidders should send their qualification documents to the designated registration email address. 2. Contact Information: Beijing Minhai Biotechnology Co., Ltd., No. 35 Simiao Road, Daxing District, Beijing. Contact persons: Mr. Hao, Ms. Fang, and Mr. Wu from the New Project Department; telephone numbers: 010‑57864910 and 010‑57864916. Registration email: mhzb@biominhai.com. VI. Registration Deadline: 5:30 p.m., October 16, 2020. Hereby announced! Beijing Minhai Biotechnology Co., Ltd. October 9, 2020

I. Project Overview Tenderer: Beijing Minhai Biotechnology Co., Ltd. Project Name: Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project – R&D Pilot‑Scale Workshop No. 1 Laboratory Design Project Project Address: No. 35 Simiao Road, Daxing District, Beijing, Bio‑Pharmaceutical Industry Base Project Overview: The Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project, invested and constructed by Beijing Minhai Biotechnology Co., Ltd., is located on parcels 0503‑039, 040, 043, and 044 within the Daxing Bio‑Pharmaceutical Industry Base. The project boundary is as follows: north to Simiao Road; south to the planned land‑use boundary (municipal green space); west to Xiangrui Avenue; and east to Tianfu Avenue. This project is primarily intended for the research, development, and production of human vaccines. Building No. 1: - Building footprint: 7,588.48 m² - Total floor area: 53,119.36 m² - Building height: 31.80 meters - Basement: 1 level, with a floor-to-floor height of 6.6 meters - Ground floors 1–3: 4.5 meters each - Floors 4–5: 6.0 meters each - Floor 6: 4.5 meters Supporting Utilities: - Power supply: sourced from the substation on the first floor, designed and constructed separately by the power authority. - Potable water: supplied by the basement softening water treatment station; process water: provided by the fourth‑floor water‑production station, both designed and built by the respective wastewater‑treatment and process‑water units. - Hot water, chilled water, and process‑chilled water: supplied by chillers installed in the basement power station; equipment specifications must be provided by the design firm. - Industrial steam: generated by the plant’s steam boiler; relevant parameters must be submitted by the design team. - Active wastewater: collected centrally in the basement waste‑liquid inactivation unit, treated, and then discharged into the municipal sewage network. - Ordinary wastewater: directly discharged into the municipal sewage system. II. Scope of Tender 1. For the Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project, specifically the R&D Pilot‑Scale Workshop No. 1 Laboratory Design Project (hereinafter referred to as “this Project”), all disciplines except architecture, structural engineering, and general interior finishing shall be covered by design and construction drawings. All construction drawings must bear the appropriate seals of the design firm and its personnel. 2. Assistance is required to enable the client‑appointed design institute to complete the architectural and structural construction drawings for this Project. 3. Provision of energy‑related requirements for this Project to the client‑appointed design institute. 4. Coordination with the general contractor responsible for interior finishing to complete the design of all ordinary laboratories, physicochemical laboratories, biochemical laboratories, and pilot‑scale workshops—covering general decoration, cleanroom finishes, and MEP systems (including but not limited to water supply, drainage, process‑chilled and hot water, industrial steam, electrical outlets, lighting, fire protection, laboratory gases, laboratory ventilation and exhaust systems, laboratory furniture, and laboratory equipment) across floors 1 through 6. 5. BIM modeling of all MEP installations for the laboratories, along with renderings of laboratory interiors; representative rooms are to be accompanied by animated walkthroughs. 6. Seamless coordination with the client‑appointed general contractor for interior finishing to ensure timely, quality‑assured, and quantity‑guaranteed completion of the project. III. Quality Standards This Project is designated as a key municipal initiative in Beijing. Its design concept must meet the following criteria: scientific rigor, user‑friendliness, standardization, intelligence, and landscape integration, aiming to remain state‑of‑the‑art for five years and avoid obsolescence within ten years. The project must comply with Chinese, EU, U.S., and WHO regulations pertaining to laboratories and pharmaceutical pilot‑scale facilities; it must also satisfy fire safety and occupational health and safety requirements. Specific standards include, but are not limited to: - “Good Manufacturing Practice for Pharmaceuticals, 2010 Edition” and its related appendices; - GB 50073 “Design Code for Cleanrooms”; - GB 50457 “Design Standard for Cleanrooms in the Pharmaceutical Industry”; - GB 50591 “Code for Construction and Acceptance of Cleanrooms”; - GBT 50314 “Standard for Intelligent Building Design”; - BSL‑2/ABSL‑2 Laboratory Planning and Design; - GB 19489 “General Requirements for Biosafety in Laboratories”; - GB 50346 “Technical Specifications for Biosafety Laboratory Buildings”; - GB 50016 “Fire Protection Design Code for Buildings”; - GB 51251 “Technical Standard for Building Smoke Control Systems”; - GB 50209 “Quality Acceptance Standard for Building Flooring Works”; - GB 50210 “Quality Acceptance Standard for Building Decoration and Finishing Works”; - GB 50243 “Quality Acceptance Standard for Ventilation and Air‑Conditioning Works”; - JGJ 91 “Design Standard for Research Buildings.” IV. Registration Instructions: 1. Participating entities must submit the following documents: business license, qualification certificates, proof of legal representative or power of attorney, and a copy of the legal representative’s ID card (copies must bear the official seal of the entity), along with an indication of the company’s registered capital. 2. Applicants must possess laboratory design qualifications, and both the applying organization and its lead design team must have demonstrated experience in designing central laboratories for national or provincial‑level institutions, as well as BSL‑2/ABSL‑2 and BSL‑3/ABSL‑3 laboratories. They should also have designed biochemical, physicochemical, or biosafety laboratories for national, provincial‑level, or Fortune Global 500 companies, and for China’s top ten pharmaceutical enterprises. Relevant visualizations and animated walkthroughs of such projects must be provided. 3. Applicants must provide contact information for a designated representative, who should serve as the project manager or primary liaison, along with proof of social insurance coverage for the past twelve months. 4. The tenderer will review the qualification documents of all applicants, giving priority to those with comparable project experience, followed by further discussions and site inspections of shortlisted candidates. 5. Beijing Minhai Biotechnology Co., Ltd. was established in 2004 and is a wholly owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. (a publicly listed company). For more information, please visit the company’s website. V. Registration Address: Beijing Minhai Biotechnology Co., Ltd. No. 35 Simiao Road, Daxing District, Beijing Contact Persons: Mr. Hao and Ms. Fang, New Project Department Telephone Numbers: 010‑57864910, 010‑57864916 Email: mhzb@biominhai.com VI. Registration Deadline: October 16, 2020, at 17:30. Hereby announced! Tenderer: Beijing Minhai Biotechnology Co., Ltd. October 9, 2020

I. Project Name: Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project II. Project Overview: The Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project, invested and developed by Beijing Minhai Biotechnology Co., Ltd., is located on parcels 0503‑039, 040, 043, and 044 within the Daxing District Biopharmaceutical Industry Base. The project’s boundaries are as follows: to the north, Simiao Road; to the south, the planned land‑use boundary (municipal green space); to the west, Xiangrui Avenue; and to the east, Tianfu Avenue. This project is primarily intended for the research, development, and production of human vaccines. The total site area is 90,013.218 m², designated as M1 Class I industrial land. The total floor area amounts to 189,820.11 m², with a building height of 33.3 meters, comprising one underground level and eight aboveground floors. The construction includes the following facilities: No. 1 R&D Pilot Workshop, No. 2 R&D Technology Workshop, No. 3 Comprehensive Service Building, No. 4 Laboratory Animal Facility, No. 5 Hazardous Waste and Dangerous Goods Storage, No. 6 Wastewater Treatment Station, No. 7 Boiler Room, No. 8 Vaccine Production Building, No. 9 Packaging and Warehousing Building, No. 10 Bacterial Vaccine Production Building, No. 12 Basement, No. 13 Gatehouse and Carport, No. 14 Gatehouse, and No. 15 Gatehouse. The main substation for the entire facility—whose cable distribution room is located inside the No. 9 Packaging and Warehousing Building—is equipped to handle a total plant‑wide load exceeding 12,000 kW. Seven distribution rooms are distributed across the aboveground buildings and underground spaces. III. Scope of Tender: This tender covers the electrical design for both the external power supply and the internal distribution system of the new base project, constituting a primary power‑supply system design tender. The external power‑supply works extend from the connection point specified in the power company‑approved installation plan to the high‑voltage switchgear section of the cable distribution room within the new base. The internal distribution system design encompasses the portion from the high‑voltage outgoing terminals at the distribution room to the low‑voltage outgoing terminals at the substation. Key design drawings include, but are not limited to: External Power Supply Works: cable trench construction drawings, cable routing diagrams, grounding system construction drawings, substation equipment foundation plans, substation layout plans, primary electrical system diagrams, secondary wiring diagrams, cable tray layouts, high‑voltage terminal diagrams, cable schedules, back‑end monitoring systems, and electrical fire‑alarm monitoring systems. Internal Distribution System Works: cable conduit burial plans, cable routing diagrams, grounding system construction drawings, substation equipment foundation plans, substation layout plans, primary electrical system diagrams, cable tray layouts, cable schedules, back‑end monitoring systems, and electrical fire‑alarm monitoring systems. IV. Design Requirements: All designs must comply with the following national and local regulations and standards: - GB 50217‑2018 “Code for Design of Power Cables” - GB 50169‑2018 “Code for Construction and Acceptance of Grounding Systems in Electrical Installations” - GB 50053‑2013 “Design Code for Substations up to 20 kV” - GB 50052‑2009 “Design Code for Power Supply and Distribution Systems” - GB 50054‑2009 “Design Code for Low‑Voltage Distribution Systems” - GB 50057‑2010 “Design Code for Lightning Protection of Buildings” - GB 50229‑2019 “Fire‑Protection Design Code for Thermal Power Plants and Substations” - GB 50116‑2013 “Design Code for Automatic Fire Alarm Systems” - DL/T 5221‑2016 “Technical Specifications for Urban Power Cable Line Design” - DLGJ 154‑2000 “Design and Construction/Acceptance Standards for Cable Fire‑Protection Measures” - Typical Design for Distribution Rooms issued by State Grid Beijing Electric Power Company. V. Relevant Requirements: 1. Timeframe: Complete the power company’s review procedures for the design drawings by December 31, 2020. 2. Contractor Responsibilities: Handle all installation and power‑supply scheme procedures—including those involving the Municipal Power Bureau, the Daxing District Power Bureau, and relevant authorities—and bear all associated costs. 3. All design content must conform to current national standards and meet all requirements for product grid‑connection certification set by the Beijing Power Department, ensuring smooth acceptance by the power bureau and successful commissioning. VI. Registration Guidelines: 1. Participating entities must submit electronic copies of their business license, qualification certificates, safety production permits, legal representative identification or corporate authorization letter, and personal ID cards. Please also indicate the registered capital of your company; supporting documentation of similar project experience may be provided concurrently. 2. Applicants must possess appropriate professional design qualifications. 3. Provide contact information for a designated representative, who should serve as the project manager or authorized liaison, along with proof of social insurance coverage for the past 12 months. 4. The tenderer will review submitted qualification documents, giving priority to applicants with comparable project experience, and will conduct further discussions and site inspections with shortlisted candidates. 5. Beijing Minhai Biotechnology Co., Ltd. was established in 2004 and is a wholly owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. (a publicly listed company). For more information, please visit the company’s official website. 6. Prior to registration, participating entities are required to engage in technical communication with our organization. VII. Registration Procedure: Please send the aforementioned materials in electronic format to mhzb@biominhai.com. Use the following subject line format: “Power Design Registration + Full Name of Organization.” Contact persons: Ms. Fang, tel. 010‑57864911; Mr. Li, tel. 010‑57864914. VIII. Registration Deadline: October 10, 2020, at 17:30. Hereby announced! Beijing Minhai Biotechnology Co., Ltd. September 23, 2020

I. Project Name: Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project II. Project Overview: The Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project, invested and developed by Beijing Minhai Biotechnology Co., Ltd., is located on parcels 0503‑039, 040, 043, and 044 within the Daxing District Biopharmaceutical Industry Base. The project’s boundaries are as follows: to the north, Simiao Road; to the south, the planned land‑use boundary (municipal green space); to the west, Xiangrui Avenue; and to the east, Tianfu Avenue. The project is primarily intended for the research, development, and production of human vaccines. The total site area is 90,013.218 m², with a land‑use designation of M1—Class I industrial land. Total…

I. Project Name: Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project II. Project Overview: The Minhai Biotechnology New‑Type Vaccine International Industrial Base Construction Project, invested and developed by Beijing Minhai Biotechnology Co., Ltd., is located on parcels 0503‑039, 040, 043, and 044 within the Daxing Biopharmaceutical Industry Base. The project’s boundaries are as follows: to the north, Simiao Road; to the south, the planned land‑use boundary (municipal green space); to the west, Xiangrui Avenue; and to the east, Tianfu Avenue. The project is primarily intended for the research, development, and production of human vaccines. 1. Construction Scale: The total land area is 90,013.218 m², with a total floor area of 187,684 m².